Impact of economic, regulatory, and patent policies on innovation in cancer chemoprevention

Cancer Prevention Research

Volumn 1, Issue 2, 2008, Pages 84-90

  Grabowski, Henry G ^a   Moe, Jeffrey L ^a  

^a DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; RALOXIFENE;

ARTICLE; CHEMOPROPHYLAXIS; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG MANUFACTURE; ECONOMICS; HUMAN; LEGAL ASPECT; LEGAL LIABILITY; MEDICAL RESEARCH; NEOPLASM; PATENT;

ANTINEOPLASTIC AGENTS; BIOMEDICAL RESEARCH; CHEMOPREVENTION; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; INTELLECTUAL PROPERTY; LIABILITY, LEGAL; NEOPLASMS; ORPHAN DRUG PRODUCTION; PATENTS AS TOPIC; RALOXIFENE;

EID: 60549086779     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-08-0048     Document Type: Article

References (29)

1. DiMasi JA, Grabowski HG. Economics of new oncology drug development. J Clin Oncol 2007;25: 209-16.
2. Herberman RB, et al. Cancer chemoprevention and cancer preventive vaccines-a call to action: leaders of diverse stakeholder groups present strategies for overcoming multiple barriers to meet an urgent need. Cancer Res 2006;66:11540-49.
3. Lippman SM, Benner SE, Hong WK. Cancer Chemoprevention. J Clin Oncol 1994;12:851-73.
4. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90: 1371-88.
5. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295: 2727-41, Erratum in: JAMA 2006;296:2926. JAMA 2007;298:973.
6. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003;22:161-3.
7. Grabowski HG, Vernon J, DiMasi JA. Returns on R & D for 1990s new drug introductions. Pharmaco Economics 2002;20:11-29.
8. Cummings SF, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281:2189-97.
9. Grabowski HG. Encouraging the development of new vaccines. Health Affairs 2005;24:697-704.
10. Grabowski HG, Vernon JM. The search for new vaccines: the effects of the vaccines for children program. Washington: AEI Press; 1997.
11. Klausner A. Mind the (biomedical funding) gap. Nat Biotechnol 2005;23:1217-8.
12. DiMasi JA, Grabowski HG. Should the patent system for new medicines be abolished? Clin Pharmacol Ther 2007;82:488-90.
13. Pammolli F, Rossi MA. Intellectual property, technological regimes and market dynamics. Economia E Politica Industriale 2005;32:87-134.
14. Nordhaus W. Invention, growth, and welfare: a theoretical treatment of technological change. Cambridge: MIT Press; 1969.
15. Scherer F, Ross D. Industrial market structure and economic performance. 3rd ed. Boston: Houghton-Mifflin; 1990.
16. Grabowski HG, Kyle M. Generic competition and market exclusivity periods in pharmaceuticals. Managerial and Decision Economics 2007;28: 491-502.
17. Long D. 2007. U.S. pharmaceutical market trends, issues, forecasts. Presented at the Generic Summit IIRA, September 17, 2007, Washington, DC.
18. Berndt ER, et al. Authorized generic drugs, price competition, and consumers' welfare. Health Aff (Millwood) 2007;26:790-9.
19. Elleman S. Problems in patent litigation: mandatory mediation may provide settlements and solutions. Ohio State Journal on Dispute Resolution 1997;12:759-78.
20. Thomas J, Schacht W. Patent reform in the 110th Congress. CRS Report RL33996. 2007. p. 1-39.
21. Lerner J. Patenting in the shadow of competitors. J Law Econ 1995;28:463-95.
22. Shellekens H. How similar do "biosimiliars" need to be? Nature Biotechnol 2004;22:1357-9.
23. Grabowski HG, Cockburn I, Long G. The market for follow-on biologics: how will it evolve? Health Aff (Millwood) 2006;25:1291-300.
24. Scherer F, Harhoff D. Technology policy for a world of skew-distributed outcomes. Research Policy 2000;29:559-66.
25. Grabowski HG. Are the economics of pharmaceutical research and development changing: productivity, patents and potential pressures. PharmacoEconomics 2004;22:15-24.
26. Towse A, Kettler H. Advance price or purchase commitments to create markets for diseases of poverty: lessons from three policies. Bulletin of the World Health Organization 2005;83.
27. Grabowski HG. 2007. Data exclusivity for new biological entities. Duke University Department of Economics Working Paper 2007;08.
28. Grabowski HG. Increasing R & D incentive for neglected disease: lessons from the orphan drug act. In: Maskus KE, Reichman JH, editors. International public goods and transfer of technology under a globalized intellectual property regime. Cambridge: Cambridge University Press; 2005.
29. NCI, 2007 "National Cancer Institute, Cancer Research Portfolio, Chemoprevention." Available at the National Cancer Institute website: http://researchportfolio.cancer.gov/projectlist.isp.